Accretion Pharmaceuticals Limited (NSE:ACCPL)

Accretion Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	21.27	40.21	0.51	0.92	0.36	3.75
Cash & Short-Term Investments	21.27	40.21	0.51	0.92	0.36	3.75
Cash Growth	1265.02%	7814.57%	-44.60%	151.92%	-90.28%	-
Accounts Receivable	319.77	224	116.61	58.05	57.99	40.68
Other Receivables	-	28.72	7.92	9.85	-	-
Receivables	374.82	252.9	124.89	68.58	57.99	40.68
Inventory	299.89	283.75	206.1	144.76	77.64	69.33
Prepaid Expenses	-	0.17	0.18	-	-	-
Other Current Assets	3.54	26.94	2.78	5.71	9.29	5.05
Total Current Assets	699.51	603.95	334.45	219.96	145.28	118.8
Property, Plant & Equipment	150.79	134.14	60.91	36.29	60.12	58.36
Other Long-Term Assets	22.49	28.07	2.62	18.14	0.39	0.26
Total Assets	873.57	766.81	398.74	274.39	205.8	177.41

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	9.27	15.89	18.39	16.4	78.5	67.37
Accrued Expenses	-	2.18	0.73	0.22	0.15	0.13
Short-Term Debt	114.48	89.79	93.9	41.56	37.4	22.26
Current Portion of Long-Term Debt	-	24.8	35.46	24.11	18.59	24.83
Current Income Taxes Payable	-	33.57	25.99	18.6	0.6	0.25
Other Current Liabilities	65.09	42.15	57.79	49.46	3.05	2.47
Total Current Liabilities	188.84	208.37	232.26	150.34	138.28	117.31
Long-Term Debt	52.89	8.63	11.68	69.11	28.67	28.99
Pension & Post-Retirement Benefits	-	-	-	-	0.44	0.34
Long-Term Deferred Tax Liabilities	2.73	2.72	1.95	0.01	-0.02	0.02
Other Long-Term Liabilities	-	-	-	-	-	0
Total Liabilities	244.47	219.72	245.88	219.46	167.37	146.65

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	111.16	111.16	81.7	40	38.43	30.76
Additional Paid-In Capital	-	268.09	-	-	-	-
Retained Earnings	517.94	167.84	71.17	14.93	-	-
Shareholders' Equity	629.1	547.09	152.87	54.93	38.43	30.76
Total Liabilities & Equity	873.57	766.81	398.74	274.39	205.8	177.41

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	167.37	123.21	141.04	134.78	84.66	76.08
Net Cash (Debt)	-146.1	-83.01	-140.53	-133.86	-84.29	-72.33
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-13.15	-7.75	-17.53	-17.61	-	-
Filing Date Shares Outstanding	11.11	11.12	8.17	8.17	-	-
Total Common Shares Outstanding	11.11	11.12	8.17	7.6	-	-
Working Capital	510.67	395.58	102.2	69.62	7	1.49
Book Value Per Share	56.61	49.22	18.71	7.23	-	-
Tangible Book Value	629.1	547.09	152.87	54.93	38.43	30.76
Tangible Book Value Per Share	56.61	49.22	18.71	7.23	-	-
Land	-	4.8	4.8	4.8	4.8	4.8
Buildings	-	48.72	22.31	-	21.02	20.12
Machinery	-	100.69	43.78	33.73	51.64	41.54
Construction In Progress	-	2.02	-	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Nov 7, 2026

Data Sources Report a data error